CRISPR-Cas9 can be used to generate CAR-T cells with DNMT3A knocked out with consequent constant proliferation and successful control of tumor development in vivo, exhibiting the benefits of targeting DNMT3A in immunotherapies (99). The gene discussed is DNMT3A; the disease is neoplasm.